Merocarb (Merocarb)
Carbapenem antibiotic — powder for solution for injection/infusion
Quick Facts About Merocarb
Key Takeaways About Merocarb
- Broad-spectrum carbapenem antibiotic: Merocarb is effective against a wide range of gram-positive and gram-negative bacteria, including many resistant strains that do not respond to other antibiotics
- Hospital use only: Administered intravenously by healthcare professionals in clinical settings; not available for home or oral use
- Critical drug interaction with valproic acid: Can reduce valproic acid levels by up to 60-100%, potentially causing breakthrough seizures — alternative anticonvulsant therapy should be considered
- Generally well tolerated: Most common side effects are gastrointestinal (diarrhea, nausea, vomiting) and injection site reactions, which are typically mild and self-limiting
- Important for resistant infections: Often reserved as a last-line treatment for multidrug-resistant bacterial infections to preserve its effectiveness against the most challenging pathogens
What Is Merocarb and What Is It Used For?
Merocarb is a carbapenem antibiotic administered intravenously to treat severe bacterial infections in hospital settings. It belongs to the beta-lactam class of antibiotics and is effective against a broad spectrum of gram-positive and gram-negative bacteria, including many multidrug-resistant organisms.
Merocarb is classified as a carbapenem, which represents one of the most potent classes of antibiotics available in clinical medicine. Carbapenems are often considered "last resort" antibiotics because of their broad-spectrum activity and their ability to overcome many common resistance mechanisms that render other beta-lactam antibiotics ineffective. Merocarb is structurally designed to resist degradation by most bacterial beta-lactamase enzymes, including extended-spectrum beta-lactamases (ESBLs) and AmpC beta-lactamases.
The drug works by inhibiting bacterial cell wall synthesis. Like other beta-lactam antibiotics, Merocarb binds to penicillin-binding proteins (PBPs) inside the bacterial cell, disrupting the cross-linking process of peptidoglycan chains that form the structural backbone of the bacterial cell wall. Without an intact cell wall, bacteria cannot maintain their osmotic integrity and ultimately undergo lysis and death. Merocarb demonstrates particularly strong binding to PBP2 and PBP3 in gram-negative bacteria, which contributes to its potent bactericidal activity.
Merocarb penetrates the outer membrane of gram-negative bacteria more effectively than many other beta-lactam antibiotics. This enhanced penetration, combined with its intrinsic stability against most beta-lactamases, allows it to reach its target PBPs at concentrations sufficient to exert bactericidal effects even against organisms that are resistant to penicillins, cephalosporins, and other antibiotic classes.
Approved Indications
Merocarb is approved for the treatment of the following serious infections in adults and children:
- Severe pneumonia including hospital-acquired and ventilator-associated pneumonia caused by susceptible organisms
- Complicated intra-abdominal infections such as peritonitis, intra-abdominal abscesses, and complicated appendicitis
- Bacterial meningitis particularly when caused by gram-negative organisms or when broad-spectrum coverage is needed
- Complicated urinary tract infections including pyelonephritis when first-line agents are not appropriate
- Complicated skin and soft tissue infections including diabetic foot infections and necrotizing fasciitis
- Septicemia and bacteremia when the causative organism is susceptible to carbapenems
- Febrile neutropenia as empirical therapy in immunocompromised patients with suspected bacterial infection
Carbapenems like Merocarb are critically important antibiotics and should be reserved for infections where narrower-spectrum agents are not appropriate. Inappropriate or excessive use of carbapenems contributes to the emergence of carbapenem-resistant organisms (CROs), which represent a major global health threat according to the WHO. Healthcare providers should always consider susceptibility data and local resistance patterns when prescribing Merocarb.
What Should You Know Before Taking Merocarb?
Before receiving Merocarb, it is essential to inform your healthcare provider about any allergies to antibiotics (especially penicillins, cephalosporins, or other carbapenems), current medications, kidney function, pregnancy or breastfeeding status, and any history of seizures or central nervous system disorders.
Merocarb is a powerful antibiotic that requires careful medical evaluation before administration. While it is generally well tolerated, certain patient populations require dose adjustments or additional monitoring. Your healthcare team will assess your medical history, current medications, and clinical status to determine whether Merocarb is the appropriate treatment for your infection.
Contraindications
Merocarb should not be administered to patients with:
- Known hypersensitivity to merocarb, any other carbapenem antibiotic, or any of the excipients in the formulation
- Severe allergic reaction history to other beta-lactam antibiotics (penicillins, cephalosporins) — while cross-reactivity between carbapenems and penicillins is low (approximately 1-3%), caution is warranted in patients with a history of anaphylaxis to beta-lactams
Warnings and Precautions
Special caution is required in the following situations:
- Seizure disorders: Carbapenems may lower the seizure threshold, particularly in patients with pre-existing central nervous system (CNS) disorders, compromised renal function, or those receiving concomitant medications that lower the seizure threshold. If focal tremors, myoclonus, or seizures occur, neurological evaluation and anticonvulsant therapy should be considered
- Renal impairment: Merocarb is primarily eliminated through the kidneys. Dose reduction is necessary in patients with creatinine clearance below 51 mL/min. Regular monitoring of renal function during treatment is recommended
- Hepatic impairment: No dose adjustment is typically required for patients with liver dysfunction, but liver function should be monitored during treatment as transient elevations in hepatic transaminases and bilirubin have been observed
- Clostridioides difficile infection: Broad-spectrum antibiotics including Merocarb can disrupt normal intestinal flora, leading to overgrowth of C. difficile and potentially life-threatening pseudomembranous colitis. If significant diarrhea develops during or after treatment, C. difficile testing should be performed
- Superinfection: Prolonged use may result in overgrowth of non-susceptible organisms, including fungi. Careful monitoring for the emergence of resistant pathogens or secondary infections is recommended
Concomitant use of Merocarb with valproic acid (or divalproex sodium) can cause a rapid and dramatic reduction in valproic acid serum levels by 60-100% within 2 days, potentially leading to loss of seizure control. This interaction is clinically significant and cannot be overcome by increasing the valproic acid dose. If carbapenem therapy is required in patients taking valproic acid, alternative anticonvulsant therapy should be initiated before starting Merocarb.
Pregnancy and Breastfeeding
The use of Merocarb during pregnancy and breastfeeding requires careful risk-benefit assessment by a qualified healthcare provider:
- Pregnancy: Animal reproductive studies have not demonstrated direct harmful effects on fetal development. However, there are limited clinical data from use in pregnant women. Merocarb should only be used during pregnancy when the potential benefit clearly justifies the potential risk to the fetus, particularly in life-threatening infections where no safer alternatives are available
- Breastfeeding: Small amounts of merocarb may be excreted in breast milk. The potential effects on the breastfed infant are not fully established. A decision should be made whether to discontinue breastfeeding or to discontinue treatment, taking into account the benefit of treatment for the mother and the importance of breastfeeding for the infant
- Fertility: Animal studies have not shown adverse effects on fertility at therapeutic doses. No human fertility studies have been conducted
How Does Merocarb Interact with Other Drugs?
Merocarb has several clinically important drug interactions. The most critical is with valproic acid, where Merocarb can reduce blood levels by up to 60-100%, potentially causing seizure breakthrough. Probenecid can increase Merocarb concentrations, and concurrent use with other nephrotoxic agents requires monitoring.
Drug interactions with carbapenems are an important consideration in clinical practice. Because patients receiving intravenous antibiotics in hospital settings are often on multiple medications simultaneously, healthcare providers must carefully review all concurrent therapies before initiating Merocarb treatment. Some interactions are well-established and clinically significant, while others require monitoring but may not necessitate medication changes.
Major Interactions
| Drug | Effect | Clinical Significance | Management |
|---|---|---|---|
| Valproic acid / Divalproex | Reduces valproic acid levels by 60-100% within 2 days | High — risk of seizure breakthrough | Avoid combination; switch to alternative anticonvulsant before starting Merocarb |
| Probenecid | Inhibits renal tubular secretion of Merocarb, increasing plasma levels and half-life | Moderate — increased drug exposure | Concomitant use not recommended; if unavoidable, monitor for adverse effects |
| Warfarin / Oral anticoagulants | May enhance anticoagulant effect and increase INR | Moderate — risk of bleeding | Monitor INR frequently; adjust warfarin dose as needed |
Minor Interactions
| Drug | Effect | Management |
|---|---|---|
| Aminoglycosides | Potential synergistic antibacterial activity but also additive nephrotoxicity | Monitor renal function closely; separate infusion times |
| Cyclosporine | Potential increase in cyclosporine levels | Monitor cyclosporine levels and renal function |
| Methotrexate | Carbapenems may reduce methotrexate elimination | Monitor methotrexate levels; be aware of potential toxicity |
Before starting Merocarb, inform your medical team about ALL medications you are currently taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins. This is especially important for anticonvulsants, blood thinners, immunosuppressants, and other antibiotics.
What Is the Correct Dosage of Merocarb?
The standard adult dose of Merocarb is 500 mg to 2 g administered intravenously every 8 hours, depending on the type and severity of infection. Dose adjustments are required for patients with impaired renal function. The drug is given either as a bolus injection over 5 minutes or as an infusion over 15-30 minutes.
Merocarb dosing is determined by the type and severity of infection, the patient's renal function, body weight (particularly in children), and the susceptibility of the causative organism. Dosing is always determined by a qualified healthcare professional and administered in a clinical setting. The following information is intended for educational purposes and should not be used for self-dosing.
Adults
| Indication | Dose | Frequency | Duration |
|---|---|---|---|
| Complicated intra-abdominal infections | 500 mg – 1 g | Every 8 hours | 5–14 days |
| Complicated skin and soft tissue infections | 500 mg | Every 8 hours | 5–14 days |
| Hospital-acquired pneumonia | 1 g | Every 8 hours | 7–14 days |
| Bacterial meningitis | 2 g | Every 8 hours | 10–14 days |
| Complicated urinary tract infections | 500 mg – 1 g | Every 8 hours | 5–14 days |
| Febrile neutropenia (empirical) | 1 g | Every 8 hours | Until resolution |
| Septicemia / Bacteremia | 1 g – 2 g | Every 8 hours | Clinician-directed |
Children
In pediatric patients aged 3 months and older, Merocarb dosing is based on body weight. The recommended dose is typically 10-40 mg/kg administered intravenously every 8 hours, depending on the type and severity of infection. For bacterial meningitis, higher doses of 40 mg/kg every 8 hours are recommended. The maximum single dose should generally not exceed the corresponding adult dose.
Pediatric Dosing Summary
- Standard infections: 10–20 mg/kg IV every 8 hours
- Severe infections and pneumonia: 20–40 mg/kg IV every 8 hours
- Meningitis: 40 mg/kg IV every 8 hours (maximum 2 g per dose)
- Neonates: Dosing in neonates younger than 3 months has not been established; use should be based on specialist guidance
Elderly
No specific dose adjustment is required in elderly patients with normal renal function. However, since kidney function naturally declines with age, renal function should be assessed before and during treatment. Many elderly patients will require reduced doses based on their creatinine clearance values. Close monitoring for adverse effects, particularly CNS effects such as confusion or seizures, is recommended in this population.
Renal Impairment Dose Adjustment
| Creatinine Clearance | Dose | Frequency |
|---|---|---|
| >51 mL/min | Standard dose | Every 8 hours |
| 26–50 mL/min | Standard dose | Every 12 hours |
| 10–25 mL/min | 50% of standard dose | Every 12 hours |
| <10 mL/min | 50% of standard dose | Every 24 hours |
Missed Dose
Since Merocarb is administered by healthcare professionals in a clinical setting, missed doses are uncommon. If a scheduled dose is inadvertently missed or delayed, it should be administered as soon as possible, and the regular dosing schedule should be resumed. The timing of subsequent doses may need to be adjusted to maintain appropriate drug levels. Do not double the dose to make up for a missed administration.
Overdose
Intentional overdose with Merocarb is unlikely given its parenteral route of administration in hospital settings. However, accidental overdose may occur, particularly in patients with impaired renal function where drug accumulation can happen. Symptoms of overdose may include nausea, vomiting, diarrhea, and neurological effects such as seizures, confusion, and tremors. In the event of overdose, treatment is supportive and symptomatic. Merocarb is dialyzable, and hemodialysis can be used to accelerate elimination in cases of significant overdose, particularly in patients with renal failure.
What Are the Side Effects of Merocarb?
Like all antibiotics, Merocarb can cause side effects. The most common include diarrhea, nausea, vomiting, headache, injection site reactions, and rash. Serious side effects such as severe allergic reactions (anaphylaxis), Clostridioides difficile-associated diarrhea, and seizures are uncommon but require immediate medical attention.
The safety profile of carbapenems has been extensively studied in clinical trials and post-marketing surveillance. Most side effects associated with Merocarb are mild to moderate in severity and resolve upon completion of treatment or dose adjustment. However, some adverse reactions can be serious and potentially life-threatening. It is important to report any unusual symptoms to your healthcare provider promptly.
The following side effects are listed by frequency according to the standard medical classification system used by regulatory authorities:
Very Common (affects more than 1 in 10 patients)
- Diarrhea
- Injection site reactions (inflammation, pain, phlebitis at infusion site)
Common (affects 1 to 10 in 100 patients)
- Nausea and vomiting
- Headache
- Rash, pruritus (itching)
- Thrombocytosis (elevated platelet count)
- Elevated hepatic transaminases (ALT, AST)
- Elevated alkaline phosphatase
- Elevated LDH
- Elevated bilirubin
- Abdominal pain
Uncommon (affects 1 to 10 in 1,000 patients)
- Oral candidiasis (oral thrush)
- Vaginal candidiasis
- Eosinophilia
- Thrombocytopenia (low platelet count)
- Leukopenia (low white blood cell count)
- Neutropenia
- Paresthesia (tingling, numbness)
- Seizures
- Clostridioides difficile colitis
- Urticaria (hives)
Rare (affects fewer than 1 in 1,000 patients)
- Anaphylaxis (severe allergic reaction)
- Angioedema (swelling of face, lips, tongue)
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis
- Hemolytic anemia
- Agranulocytosis (severe drop in white blood cells)
- Drug reaction with eosinophilia and systemic symptoms (DRESS)
- Acute generalized exanthematous pustulosis (AGEP)
Difficulty breathing, swelling of face/lips/tongue/throat, severe skin reactions (widespread rash with blistering or peeling), severe or persistent diarrhea (especially if bloody or watery), seizures, or signs of a severe allergic reaction. These may indicate life-threatening conditions requiring emergency treatment.
Healthcare providers monitoring patients on Merocarb should perform regular blood tests to check liver function, kidney function, and blood cell counts. Patients should be observed for signs of superinfection with resistant organisms, particularly during prolonged courses of therapy. The development of seizures, especially in patients with pre-existing CNS disorders or renal impairment, requires prompt evaluation and possible discontinuation of the drug.
How Should You Store Merocarb?
Merocarb powder for injection/infusion should be stored below 30°C in its original packaging. Once reconstituted, the solution should be used within the timeframe specified by the manufacturer and stored according to pharmacy guidelines. Do not freeze.
Proper storage of Merocarb is essential to ensure the drug's stability, potency, and safety. As a hospital-administered medication, storage is typically managed by pharmacy and nursing staff according to institutional protocols. The following storage guidelines apply:
- Unopened vials: Store below 30°C (86°F) in the original carton to protect from light. Do not freeze the dry powder
- Reconstituted solution (room temperature): When reconstituted with sterile water for injection, the solution should be used immediately or within 3 hours if stored at room temperature (15-25°C). Chemical and physical in-use stability has been demonstrated for up to 3 hours at 25°C
- Reconstituted solution (refrigerated): If not used immediately, the reconstituted solution may be stored under refrigeration (2-8°C) for up to 24 hours. Once removed from the refrigerator, the solution should be used within 3 hours
- Diluted infusion solution: When diluted in compatible infusion fluids (0.9% sodium chloride or 5% glucose), stability may vary. Refer to the specific product information for compatibility and stability data
- Do not freeze reconstituted or diluted solutions
- Visual inspection: Before administration, the reconstituted solution should be visually inspected. It should be a clear to yellow solution. Do not use if the solution is cloudy, discolored, or contains particulate matter
As with all medications, keep Merocarb out of the reach of children. Do not use the drug after the expiry date printed on the vial and carton. Return unused or expired medication to the pharmacy for proper disposal. Do not dispose of medications via household waste or wastewater.
What Does Merocarb Contain?
Each vial of Merocarb contains merocarb as the active substance (1 g per vial) along with sodium carbonate as an excipient to adjust pH and aid dissolution. When reconstituted, the solution contains approximately 90 mg (approximately 4 mmol) of sodium per vial.
Understanding the composition of Merocarb is important for healthcare providers managing patients with specific allergies, dietary restrictions (such as sodium-controlled diets), or drug sensitivities. The following information details the active and inactive ingredients:
Active Ingredient
- Merocarb: 1 g per vial (as merocarb trihydrate). The active substance is a synthetic carbapenem antibiotic with a molecular structure that confers broad-spectrum antibacterial activity and stability against most beta-lactamase enzymes
Excipients
- Anhydrous sodium carbonate: Used as a pH adjuster to ensure the reconstituted solution falls within the appropriate pH range (7.3-8.3) for intravenous administration. Also aids in dissolution of the powder
Sodium Content
Each 1 g vial of Merocarb contains approximately 90 mg of sodium (approximately 3.9 mmol). This should be taken into consideration for patients on a sodium-restricted diet, patients with heart failure, or patients receiving concomitant sodium-containing intravenous fluids. When multiple daily doses are administered (e.g., 1 g every 8 hours), the total daily sodium contribution from Merocarb alone may be approximately 270 mg (approximately 11.7 mmol).
Physical Description
Merocarb powder for solution for injection/infusion is a white to pale yellow crystalline powder supplied in clear glass vials with rubber stoppers and aluminum seals. Each vial contains 1 g of merocarb. The powder is for single use only; any unused solution remaining after administration should be discarded.
Frequently Asked Questions About Merocarb
References
This article is based on the following peer-reviewed sources and international medical guidelines:
- European Medicines Agency (EMA). Summary of Product Characteristics — Meropenem-class products. Available at: www.ema.europa.eu
- World Health Organization (WHO). Model List of Essential Medicines, 23rd List (2023). Carbapenems are listed as critically important antimicrobials. Available at: www.who.int
- Infectious Diseases Society of America (IDSA). Practice Guidelines for the Diagnosis and Management of Complicated Intra-Abdominal Infection in Adults and Children (2024 Update). Clinical Infectious Diseases.
- Nicolau DP. Pharmacodynamic optimization of beta-lactams in the patient care setting. Critical Care. 2008;12(Suppl 4):S2. doi:10.1186/cc6818
- Baldwin CM, Lyseng-Williamson KA, Keam SJ. Meropenem: a review of its use in the treatment of serious bacterial infections. Drugs. 2008;68(6):803-838.
- Linden P. Safety profile of meropenem: an updated review of over 6,000 patients treated with meropenem. Drug Safety. 2007;30(8):657-668.
- Mori H, Takahashi K, Mizutani T. Interaction between valproic acid and carbapenem antibiotics. Drug Metabolism Reviews. 2007;39(4):647-657.
- British National Formulary (BNF). Meropenem. National Institute for Health and Care Excellence. Available at: bnf.nice.org.uk
- WHO Advisory Group on Integrated Surveillance of Antimicrobial Resistance (AGISAR). Critically Important Antimicrobials for Human Medicine, 6th Revision (2018). Geneva: World Health Organization.
- Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: past, present, and future. Antimicrobial Agents and Chemotherapy. 2011;55(11):4943-4960. doi:10.1128/AAC.00296-11
About Our Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed healthcare professionals with expertise in clinical pharmacology, infectious disease, and antimicrobial therapy.
Content developed by specialist physicians with training in clinical pharmacology and evidence-based medicine. All medical claims are supported by peer-reviewed research and international guidelines.
Independently reviewed by the iMedic Medical Review Board according to WHO, EMA, FDA, and IDSA guidelines. Evidence graded using the GRADE framework with a focus on Level 1A evidence from systematic reviews and randomized controlled trials.
All content adheres to international medical editorial standards, with no pharmaceutical funding or commercial influence. Regular updates ensure accuracy as new evidence emerges.
This page is designed to meet WCAG 2.2 Level AAA standards, ensuring access for all users regardless of ability. Content is structured for screen readers, keyboard navigation, and assistive technologies.